Overview

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2017-05-05
Target enrollment:
Participant gender:
Summary
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the response rate, as determined by the revised International Working Group recommendations.
Phase:
Phase 2
Details
Lead Sponsor:
Polaris Group